3Biasucci LM.Role ofinflammation in the pathogenesis on unstable coronary artery disease[J].Scand J Clin Lab Invent,1999,59(suppl230):12-20.
4Canthin B,Despues JP,Lamarche B,et al.Association of fibrinogen and lipoprotein (a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study)[J].Am J Cardiol,2002,89 (6):662-666.
5Germing A,Von Dryanders,Machraoui A,et al.Hyperfibrinigenemia increase the risk of cardiac events after coronary artery stenting[J].Heart Vessels,2000,15 (6):263-267.
6Angelides NS,Minas C.Can aortocoronary by improved by the administation of pentoxifylline on a long-term basis[J].Cardiology,1999,44 (12):1059-1064.
7John E. Oxidative stress in chronic obstructive pulmonary disease. Am J Resoir Crit Care Med. 1997, 156:341-357.
8Graninger W, Wenish C. Pentoxifylline in severe inflammatory response syndrome. J Cardiovas Pharma, 1995, (suppl. 2): 134～ 138.
9Poulakis N, Androutsos G, Kazi D, et al. The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications: Respir Med, 1999, 930: 52-57.
10Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir carit care Med, 1996, 153: 530-534.
